Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy

Sliwa, Karen; Woodiwiss, Angela J.; Candy, Geoffrey P.; Badenhorst, Danelle; Libhaber, Carlos D.; Norton, Gavin R.; Skudicky, Daniel; Sareli, Pinhas

doi:10.1016/s0002-9149(02)02779-0

Cited by 87 publications

(64 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pentoxifylline, an agent known to inhibit TNF-α production, among other physiologic effects, has similarly shown favorable effects of HF symptoms and ejection fraction in preliminary studies. 34,35 These promising data will require confirmation in larger studies.…”

Section: Modulation Of Inflammation In Hfmentioning

confidence: 95%

Inflammatory Biomarkers in Heart Failure

Petersen

Felker

2006

Congestive Heart Failure

View full text Add to dashboard Cite

Multiple lines of evidence support the “cytokine hypothesis,” which suggests that inflammation plays an important role in the development and progression of heart failure. Circulating markers of inflammation, such as tumor necrosis factor α, interleukin 6, and C‐reactive protein, may be useful in establishing the diagnosis, gauging prognosis, and evaluating the response to therapy in patients with heart failure. In addition to their potential as heart failure biomarkers, inflammatory cytokines have been investigated as targets of heart failure therapy. Although results for therapies directed against specific cytokines (such as tumor necrosis factor α) have thus far been disappointing, multiple studies continue to address the therapeutic potential of modulating the immune response in heart failure. In this review, the authors analyze available data supporting the use of inflammatory markers both as biomarkers and as potential therapeutic targets.

show abstract

Section: Modulation Of Inflammation In Hfmentioning

confidence: 95%

Inflammatory Biomarkers in Heart Failure

Petersen

Felker

2006

Congestive Heart Failure

View full text Add to dashboard Cite

show abstract

“…The first six studies [5][6][7][8][9][10] are from a single center with a meta-analysis already performed for the five randomized studies [11]. One of these studies was excluded because of its before/after design [8].…”

Section: Resultsmentioning

confidence: 99%

“…This study showed a significant decrease in hospital mortality in peripartum cardiomyopathy over time after introduction of pentoxifylline in the therapeutic armatorium. No duplicate publication or patients' overlap was acknowledged in the six trials conducted in Baragwanath Hospital in Johannesburg [5][6][7]9,10]. The last study included in our meta-analysis was performed by a different center in a different country [12].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Pentoxifylline in Heart Failure: A Meta‐Analysis of Clinical Trials

Champion

Lapidus

Cherié³

et al. 2014

Cardiovascular Therapeutics

View full text Add to dashboard Cite

Background: Pentoxifylline possess antiinflammatory and rheological properties and has been tested in heart failure (HF). Methods: A comprehensive search was performed from 1980 until July 2013 in PubMed, to identify randomized controlled trials evaluating pentoxifylline versus placebo in HF, to determine impact on mortality. Search strategy is as follows: "Pentoxifylline" AND "heart" AND "trial". Study selection of six randomized controlled trials evaluating mortality as outcome. Then, we conducted a meta-analysis of randomized controlled trials versus placebo in HF. Determination of Mantel-Haenszel fixed effect and random-effect pooled odds ratios for all-cause mortality and corresponding 95% confidence intervals. Results: Data from a total of 221 patients with LVEF ≤40% from six randomized controlled trials were included in this analysis. Pentoxifylline 1200 mg per day was administered during 6 months, except in one study (administered during 1 month for severe acute HF). The use of pentoxifylline was not significantly associated with a reduction in mortality in HF in individual studies. The pooled data including 221 patients showed a nearly fourfold reduction in mortality (5.4% vs. 18.3%; OR 0.29; CI 0.12-0.74; P < 0.01) with homogenous results (I² 0%). Conclusion: A meta-analysis evaluating pentoxifylline versus placebo in HF suggested a significant nearly fourfold decrease in all-cause mortality in the pentoxifylline group.

show abstract

“…The importance of inflammation has been highlighted in animal models and in patients. (6,12,13) Cardiac fibrosis has been demonstrated in PPCM animal models, but has not yet been explored in patients. (4) PPCM is a disease which progresses quickly to cardiac dysfunction and failure.…”

mentioning

confidence: 99%

Heart rate – a novel target for treatment of peripartum cardiomyopathy?

Imamdin

Lecour

Opie

et al. 2017

SAHJ

Self Cite

View full text Add to dashboard Cite

the case with PPCM patients as they continue to display an elevated HR 6 months after delivery which represents 6 times the duration of normal recovery (Figure 1). ABSTRACTPeripartum Cardiomyopathy (PPCM) is a maternal condition which manifests with symptoms of heart failure between the last month of pregnancy and 5 months postpartum.(1) It is an important health concern in the sub-Saharan region of Africa, with approximately 1 in 1 000 pregnant women affected by the condition in South Africa.(2)

show abstract

Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy

Cited by 87 publications

References 15 publications

Inflammatory Biomarkers in Heart Failure

Inflammatory Biomarkers in Heart Failure

Pentoxifylline in Heart Failure: A Meta‐Analysis of Clinical Trials

Heart rate – a novel target for treatment of peripartum cardiomyopathy?

Contact Info

Product

Resources

About